Mattijs Elschot1, Kirsten M Selnæs2,3, Elise Sandsmark2, Brage Krüger-Stokke2,4, Øystein Størkersen5, Guro F Giskeødegård2,3, May-Britt Tessem2, Siver A Moestue6, Helena Bertilsson7,8, Tone F Bathen2,3. 1. Department of Circulation and Medical Imaging, NTNU: Norwegian University of Science and Technology, Trondheim, Norway mattijs.elschot@ntnu.no. 2. Department of Circulation and Medical Imaging, NTNU: Norwegian University of Science and Technology, Trondheim, Norway. 3. St. Olavs Hospital, Trondheim, Norway. 4. Department of Radiology, St. Olavs Hospital, Trondheim, Norway. 5. Department of Pathology, St. Olavs Hospital, Trondheim, Norway. 6. Department of Laboratory Medicine, Children's and Women's Health, NTNU: Norwegian University of Science and Technology, Trondheim, Norway. 7. Department of Urology, St. Olavs Hospital, Trondheim, Norway; and. 8. Department of Cancer Research and Molecular Medicine, NTNU: Norwegian University of Science and Technology, Trondheim, Norway.
Abstract
The objective of this study was to investigate whether quantitative imaging features derived from combined 18F-fluciclovine PET/multiparametric MRI show potential for detection and characterization of primary prostate cancer. Methods: Twenty-eight patients diagnosed with high-risk prostate cancer underwent simultaneous 18F-fluciclovine PET/MRI before radical prostatectomy. Volumes of interest (VOIs) for prostate tumors, benign prostatic hyperplasia (BPH) nodules, prostatitis, and healthy tissue were delineated on T2-weighted images, using histology as a reference. Tumor VOIs were marked as high-grade (≥Gleason grade group 3) or not. MRI and PET features were extracted on the voxel and VOI levels. Partial least-squared discriminant analysis (PLS-DA) with double leave-one-patient-out cross-validation was performed to distinguish tumors from benign tissue (BPH, prostatitis, or healthy tissue) and high-grade tumors from other tissue (low-grade tumors or benign tissue). The performance levels of PET, MRI, and combined PET/MRI features were compared using the area under the receiver-operating-characteristic curve (AUC). Results: Voxel and VOI features were extracted from 40 tumor VOIs (26 high-grade), 36 BPH VOIs, 6 prostatitis VOIs, and 37 healthy-tissue VOIs. PET/MRI performed better than MRI and PET alone for distinguishing tumors from benign tissue (AUCs of 87%, 81%, and 83%, respectively, at the voxel level and 96%, 93%, and 93%, respectively, at the VOI level) and high-grade tumors from other tissue (AUCs of 85%, 79%, and 81%, respectively, at the voxel level and 93%, 93%, and 91%, respectively, at the VOI level). T2-weighted MRI, diffusion-weighted MRI, and PET features were the most important for classification. Conclusion: Combined 18F-fluciclovine PET/multiparametric MRI shows potential for improving detection and characterization of high-risk prostate cancer, in comparison to MRI and PET alone.
The objective of this study was to investigate whether quantitative imaging features derived from combined 18F-fluciclovine PET/multiparametric MRI show potential for detection and characterization of primary prostate cancer. Methods: Twenty-eight patients diagnosed with high-risk prostate cancer underwent simultaneous 18F-fluciclovine PET/MRI before radical prostatectomy. Volumes of interest (VOIs) for prostate tumors, benign prostatic hyperplasia (BPH) nodules, prostatitis, and healthy tissue were delineated on T2-weighted images, using histology as a reference. Tumor VOIs were marked as high-grade (≥Gleason grade group 3) or not. MRI and PET features were extracted on the voxel and VOI levels. Partial least-squared discriminant analysis (PLS-DA) with double leave-one-patient-out cross-validation was performed to distinguish tumors from benign tissue (BPH, prostatitis, or healthy tissue) and high-grade tumors from other tissue (low-grade tumors or benign tissue). The performance levels of PET, MRI, and combined PET/MRI features were compared using the area under the receiver-operating-characteristic curve (AUC). Results: Voxel and VOI features were extracted from 40 tumor VOIs (26 high-grade), 36 BPH VOIs, 6 prostatitis VOIs, and 37 healthy-tissue VOIs. PET/MRI performed better than MRI and PET alone for distinguishing tumors from benign tissue (AUCs of 87%, 81%, and 83%, respectively, at the voxel level and 96%, 93%, and 93%, respectively, at the VOI level) and high-grade tumors from other tissue (AUCs of 85%, 79%, and 81%, respectively, at the voxel level and 93%, 93%, and 91%, respectively, at the VOI level). T2-weighted MRI, diffusion-weighted MRI, and PET features were the most important for classification. Conclusion: Combined 18F-fluciclovine PET/multiparametric MRI shows potential for improving detection and characterization of high-risk prostate cancer, in comparison to MRI and PET alone.
Authors: Divya Yadav; Hyunsoo Hwang; Wei Qiao; Rituraj Upadhyay; Brian F Chapin; Chad Tang; Ana Aparicio; Maria A Lopez-Olivo; Stella K Kang; Homer A Macapinlac; Tharakeswara K Bathala; Devaki Shilpa Surasi Journal: Radiol Imaging Cancer Date: 2022-03
Authors: Barbara J Amorim; Vinay Prabhu; Sara S Marco; Debra Gervais; Willian E Palmer; Pedram Heidari; Mark Vangel; Philip J Saylor; Onofrio A Catalano Journal: Eur J Nucl Med Mol Imaging Date: 2019-09-06 Impact factor: 9.236
Authors: Morteza Esmaeili; Nassim Tayari; Tom Scheenen; Mattijs Elschot; Elise Sandsmark; Helena Bertilsson; Arend Heerschap; Kirsten M Selnæs; Tone F Bathen Journal: Front Oncol Date: 2018-11-15 Impact factor: 6.244
Authors: Andrew M McDonald; Samuel J Galgano; Jonathan E McConathy; Eddy S Yang; Michael C Dobelbower; Rojymon Jacob; Soroush Rais-Bahrami; Jeffrey W Nix; Richard A Popple; John B Fiveash Journal: Adv Radiat Oncol Date: 2019-06-19